A phase I study of subcutaneously administered Campath in CD52 expressing hematologic malignancies

Trial Profile

A phase I study of subcutaneously administered Campath in CD52 expressing hematologic malignancies

Discontinued
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2013

At a glance

  • Drugs Alemtuzumab (Primary)
  • Indications Chronic lymphocytic leukaemia; Myeloma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Sanofi Genzyme
  • Most Recent Events

    • 19 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top